Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis
News
Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical ... Read more